The country#39;s largest airline with a domestic market share of little over 60 per cent is also betting big on A321 XLR aircraft that are expected to be part of its fleet “somewhere in 2025”, to further expand its overseas presence.

Read More

​ The country#39;s largest airline with a domestic market share of little over 60 per cent is also betting big on A321 XLR aircraft that are expected to be part of its fleet “somewhere in 2025”, to further expand its overseas presence. The country#39;s largest airline with a domestic market share of little over 60 per cent is also betting big on A321 XLR aircraft that are expected to be part of its fleet “somewhere in 2025”, to further expand its overseas presence.  Moneycontrol Latest News Read More  

The country#39;s largest airline with a domestic market share of little over 60 per cent is also betting big on A321 XLR aircraft that are expected to be part of its fleet “somewhere in 2025”, to further expand its overseas presence.

The country#39;s largest airline with a domestic market share of little over 60 per cent is also betting big on A321 XLR aircraft that are expected to be part of its fleet “somewhere in 2025”, to further expand its overseas presence.

Read More

​ The country#39;s largest airline with a domestic market share of little over 60 per cent is also betting big on A321 XLR aircraft that are expected to be part of its fleet “somewhere in 2025”, to further expand its overseas presence. The country#39;s largest airline with a domestic market share of little over 60 per cent is also betting big on A321 XLR aircraft that are expected to be part of its fleet “somewhere in 2025”, to further expand its overseas presence.  Moneycontrol Latest News Read More  

The country#39;s largest airline with a domestic market share of little over 60 per cent is also betting big on A321 XLR aircraft that are expected to be part of its fleet “somewhere in 2025”, to further expand its overseas presence.

Geojit Financial Services recommended accumulate rating on NATCO Pharma with a target price of Rs 1116 in its research report dated March 27, 2024.

Read More

​ Geojit Financial Services recommended accumulate rating on NATCO Pharma with a target price of Rs 1116 in its research report dated March 27, 2024. Geojit Financial Services recommended accumulate rating on NATCO Pharma with a target price of Rs 1116 in its research report dated March 27, 2024.  Moneycontrol Latest News Read More  

Geojit Financial Services recommended accumulate rating on NATCO Pharma with a target price of Rs 1116 in its research report dated March 27, 2024.

Reports have said that Standard Chartered#39;s corporate banking section was looking to unload its entire 7.18 percent stake in CDSL for at least $151 million.

Read More

​ Reports have said that Standard Chartered#39;s corporate banking section was looking to unload its entire 7.18 percent stake in CDSL for at least $151 million. Reports have said that Standard Chartered#39;s corporate banking section was looking to unload its entire 7.18 percent stake in CDSL for at least $151 million.  Moneycontrol Latest News Read More  

Reports have said that Standard Chartered#39;s corporate banking section was looking to unload its entire 7.18 percent stake in CDSL for at least $151 million.

The meeting began at 11 a.m. (0300 GMT) following the taking of a group photo, the report said. An accompanying video showed the attendees would be sat in a square formation, with the two fully visible sides both set out with seven seats each.

Read More

​ The meeting began at 11 a.m. (0300 GMT) following the taking of a group photo, the report said. An accompanying video showed the attendees would be sat in a square formation, with the two fully visible sides both set out with seven seats each. The meeting began at 11 a.m. (0300 GMT) following the taking of a group photo, the report said. An accompanying video showed the attendees would be sat in a square formation, with the two fully visible sides both set out with seven seats each.  Moneycontrol Latest News Read More  

The meeting began at 11 a.m. (0300 GMT) following the taking of a group photo, the report said. An accompanying video showed the attendees would be sat in a square formation, with the two fully visible sides both set out with seven seats each.

Goldman Sachs believes RIL#39;s consolidated returns are at an inflection point in FY24, and its Cash Return on Cash Invested (CROCI) will expand by nearly 270 basis points to 12 percent in FY27, which will be the highest since 2011.

Read More

​ Goldman Sachs believes RIL#39;s consolidated returns are at an inflection point in FY24, and its Cash Return on Cash Invested (CROCI) will expand by nearly 270 basis points to 12 percent in FY27, which will be the highest since 2011. Goldman Sachs believes RIL#39;s consolidated returns are at an inflection point in FY24, and its Cash Return on Cash Invested (CROCI) will expand by nearly 270 basis points to 12 percent in FY27, which will be the highest since 2011.  Moneycontrol Latest News Read More  

Goldman Sachs believes RIL#39;s consolidated returns are at an inflection point in FY24, and its Cash Return on Cash Invested (CROCI) will expand by nearly 270 basis points to 12 percent in FY27, which will be the highest since 2011.

Shyam Metalics Energy | The LoI is valid for a period of one year from the date of issuance.

Read More

​ Shyam Metalics Energy | The LoI is valid for a period of one year from the date of issuance. Shyam Metalics Energy | The LoI is valid for a period of one year from the date of issuance.  Moneycontrol Latest News Read More  

Shyam Metalics Energy | The LoI is valid for a period of one year from the date of issuance.

Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category

Read More

​ Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category  Moneycontrol Latest News Read More  

Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category

Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category

Read More

​ Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category  Moneycontrol Latest News Read More  

Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category

Traders should limit their exposure and prefer hedged trades, with a focus on index majors and large midcaps, says Ajit Mishra of Religare Broking

Read More

​ Traders should limit their exposure and prefer hedged trades, with a focus on index majors and large midcaps, says Ajit Mishra of Religare Broking Traders should limit their exposure and prefer hedged trades, with a focus on index majors and large midcaps, says Ajit Mishra of Religare Broking  Moneycontrol Latest News Read More  

Traders should limit their exposure and prefer hedged trades, with a focus on index majors and large midcaps, says Ajit Mishra of Religare Broking